Sign In
Buy MBRX
$0.400
-0.620 (-60.78%)
At Close: Jul 31, 2026
Company on track for first subject treated in pivotal, adaptive Phase 3 clinical trial (the "MIRACLE" trial) in the first quarter of 2025 Trial designed for possible accelerated approval of Annamycin
Moleculin Biotech, Inc. (MBRX) Q3 2024 Earnings Call Transcript
11:17am, Monday, 11'th Nov 2024
Moleculin Biotech, Inc. (NASDAQ:MBRX ) Q3 2024 Earnings Conference Call November 11, 2024 8:30 AM ET Company Participants Jenene Thomas - IR Walter Klemp - Chairman and CEO John Paul Waymack - Senior
Moleculin Reports Third Quarter 2024 Financial Results and Provides Corporate Update
07:05am, Monday, 11'th Nov 2024
- On track to start dosing in pivotal, adaptive Phase 3 clinical trial (the "MIRACLE" trial) designed for possible accelerated approval of Annamycin in combination with cytarabine for the treatment of
Moleculin to Report Third Quarter 2024 Financial Results on November 8, 2024 and Host Conference Call and Webcast
09:00am, Tuesday, 05'th Nov 2024
HOUSTON , Nov. 5, 2024 /PRNewswire/ -- Moleculin Biotech, Inc., (Nasdaq: MBRX) ("Moleculin" or the "Company"), a late-stage pharmaceutical company with a broad portfolio of drug candidates targeting h
Moleculin Appoints Leading Expert in Pancreatic Cancer to its Scientific Advisory Board to Support Development of Annamycin
08:30am, Monday, 04'th Nov 2024
Strong preclinical evidence of Annamycin's potential for treating pancreatic cancer presented at AACR expands collaboration HOUSTON , Nov. 4, 2024 /PRNewswire/ -- Moleculin Biotech, Inc. , (Nasdaq: MB
Transcript from Moleculin's Recent Virtual Acute Myeloid Leukemia KOL Event Now Available
08:40am, Thursday, 17'th Oct 2024
Access the transcript here HOUSTON , Oct. 17, 2024 /PRNewswire/ -- Moleculin Biotech, Inc., (Nasdaq: MBRX) ("Moleculin" or the "Company"), a late stage pharmaceutical company with a broad portfolio of
Moleculin to Host Virtual Acute Myeloid Leukemia KOL Event on October 14, 2024
08:30am, Monday, 07'th Oct 2024
Live webcast discussion featuring internationally renowned Acute Myeloid Leukemia (AML) Key Opinion Leaders Ongoing progress of pivotal, adaptive Phase 3 clinical trial (the "MIRACLE" trial) designed
Moleculin to Present at Two Upcoming Investor Conferences
09:00am, Friday, 04'th Oct 2024
HOUSTON , Oct. 4, 2024 /PRNewswire/ -- Moleculin Biotech, Inc., (Nasdaq: MBRX) ("Moleculin" or the "Company"), a late stage pharmaceutical company with a broad portfolio of drug candidates targeting h
Moleculin Announces Positive In Vivo Efficacy Data of Annamycin in Orthotopic and Experimental Lung Metastatic Models of Sarcoma
08:00am, Monday, 23'rd Sep 2024
Data recently presented at the International Association for the Study of Lung Cancer (IASLC) 2024 World Conference on Lung Cancer Treatment with Annamycin results in statistically significant inhibit
Moleculin Participates in Virtual Investor "What this Means" Segment
08:30am, Monday, 16'th Sep 2024
Wally Klemp, CEO of Moleculin, discusses the Company's recent update on the Phase 2 clinical trial of STAT3 inhibitor in combination with radiation for the treatment of glioblastoma Watch the "What Th
– Investigator-initiated Phase 2 study is being conducted at Northwestern University in cooperation with Moleculin – Funding for study provided by NIH and BrainUp® – Trial combines WP1066 and r
Moleculin to Present at the H.C. Wainwright 26th Annual Global Investment Conference
09:15am, Tuesday, 03'rd Sep 2024
HOUSTON , Sept. 3, 2024 /PRNewswire/ -- Moleculin Biotech, Inc., (Nasdaq: MBRX) ("Moleculin" or the "Company"), a Phase 3 clinical stage pharmaceutical company with a broad portfolio of drug candidate
Moleculin to Present at LIVE! with Webull Corporate Connect: Healthcare Investment Webinar
08:30am, Monday, 26'th Aug 2024
Live webcast on Wednesday, August 28 th at 3:40 PM ET HOUSTON , Aug. 26, 2024 /PRNewswire/ -- Moleculin Biotech, Inc., (Nasdaq: MBRX) ("Moleculin" or the "Company"), a Phase 3 clinical stage pharmace
Moleculin Announces Closing of up to $16.5 Million Public Offering
04:05pm, Monday, 19'th Aug 2024
$5.5 million financing upfront with up to an additional $11.0 million of potential aggregate gross proceeds upon the exercise in full of milestone-linked warrants HOUSTON , Aug. 19, 2024 /PRNewswire/
Moleculin Reports Second Quarter 2024 Financial Results and Provides Corporate Update
08:05am, Wednesday, 14'th Aug 2024
- Positive outcome from End of Phase 1B/2 Meeting with FDA - Company proceeding with a pivotal, adaptive Phase 3 clinical trial (the "MIRACLE" trial) designed for possi
